Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

More Americans are beating cancer than ever, yet many still grapple with treatment's long shadow - especially on their mental health.

More Americans are beating cancer than ever, yet many still grapple with treatment's long shadow—especially on their mental ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

An immunotherapy treatment could ‘change the world’ for newly diagnosed head and neck cancer patients by giving them an extra ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...